| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$249 |
Equity Raising Presentation
|
26 Feb 2026 9:25AM |
$1.715 |
$0.370 |
fallen by
78.43%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Bapcor Limited is undertaking a $200 million equity raising to strengthen its balance sheet.
- The equity raising includes a 1 for 1.36 pro rata accelerated non-renounceable entitlement offer and a 'pro rata' institutional placement.
- The offer price for new shares is set at $0.60, representing significant discounts to the previous trading price.
- Proceeds from the equity raising will be used primarily to reduce Bapcor's debt.
- Bapcor's lenders have agreed to temporarily lower certain financial covenants, providing flexibility for the company.
- The company aims to reduce its net leverage ratio to between 1.2x and 1.5x by 30 June 2026.
- New leadership has been appointed to focus on operational turnaround and improving performance.
- Bapcor anticipates operational improvements through enhanced inventory management and cost controls.
- The equity raising is fully underwritten, ensuring the capital will be raised as planned.
- Bapcor faces ongoing competitive pressures and supply chain challenges that have impacted recent financial performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Swoop Holdings Limited (SWP) ORDINARY FULLY PAID |
Communication Services |
$26 |
SWP 1HFY26 Investor Briefing
|
26 Feb 2026 9:25AM |
$0.150 |
$0.084 |
fallen by
44%
|
|
SWP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 41% YoY in 1H FY26.
- Underlying EBITDA decreased by 10%.
- Organic growth in Internet, Data, and Mobile services by 27%.
- Significant projects include the Melbourne Fibre rollout.
- Completed $6.2m divestment of Vonex shares.
- Raised $10 million through an Entitlement Offer.
- Available funding of $16 million as of December 2025.
- Targeting 5-10% margin improvement in core products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| The Calmer Co International Limited (CCO) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
The Calmer Co raises $1.6m in placement
|
26 Feb 2026 9:25AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
CCO - Price-sensitive ASX Announcement
Full Release
Key Points
- The Calmer Co raised $1.6 million in a successful and oversubscribed placement.
- Funds will accelerate U.S. expansion and marketing efforts for kava products.
- The placement was well supported by new and existing investors.
- Novus Capital Limited acted as the Lead Manager for the placement.
- The company aims to enhance its market position in the functional relaxation category.
- The placement included 457,142,858 fully paid ordinary shares with free attaching options.
- Funds also allocated for inventory build and general working capital.
- The global kava market is projected to grow significantly, reaching US$5.6 billion by 2033.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$96 |
Appendix 4D and HY26 Financial Statements
|
26 Feb 2026 9:25AM |
$0.700 |
$0.680 |
fallen by
2.86%
|
|
CAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax of $5,100,370 for half-year ended 31 December 2025.
- Revenue from ordinary activities increased significantly due to favorable market conditions.
- Issued new convertible notes and maintained a dividend reinvestment plan.
- Improved financial performance attributed to higher dividend and trust distributions.
- Appendix 4D details financial highlights and dividend declarations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$249 |
1H26 Results Presentation
|
26 Feb 2026 9:25AM |
$1.715 |
$0.370 |
fallen by
78.43%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue and EBITDA declined across all segments.
- Significant items include impairments and restructuring costs.
- Focus on strategic initiatives to improve profitability and efficiency.
- Statutory loss of $104.8M due to significant items.
- New leadership focused on returning to growth and enhancing performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$87 |
FY26 Half Year Financial Results Presentation
|
26 Feb 2026 9:25AM |
$0.265 |
$0.140 |
fallen by
47.17%
|
|
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$249 |
2026 Half Year Financial Results, Outlook and Equity Raising
|
26 Feb 2026 9:25AM |
$1.715 |
$0.370 |
fallen by
78.43%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Bapcor reported a statutory loss of $104.8 million including significant items of $110.3 million post-tax.
- Underlying group revenue was $973 million, a decrease of 2.3% from the previous period.
- Underlying Net Profit After Tax (NPAT) was $5.5 million, consistent with guidance.
- Net debt increased to $387.3 million, but the company maintained compliance with debt covenants.
- A $200 million fully underwritten equity raising was announced to enhance financial flexibility.
- No interim dividend was declared.
- The company is focusing on strategic imperatives including optimizing the network and simplifying core business processes.
- Significant items include a $99.9 million non-cash impairment of assets in New Zealand due to challenging macroeconomic conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bapcor Limited (BAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$249 |
Appendix 4D and Half Year Financial Report
|
26 Feb 2026 9:24AM |
$1.715 |
$0.370 |
fallen by
78.43%
|
|
BAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Bapcor Limited reported a loss after income tax benefit of $104.641 million.
- Revenue for the half-year was $973.028 million.
- Significant expenses included impairments of goodwill and assets.
- Cash flow from operating activities remained positive.
- Report details strategic realignments within Bapcor's operations.
- Net assets decreased significantly.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Saluda Medical, Inc. (SLD) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$101 |
H1 FY2026 Results Announcement
|
26 Feb 2026 9:24AM |
$0.990 |
$0.400 |
fallen by
59.60%
|
|
SLD - Price-sensitive ASX Announcement
Full Release
Key Points
- Saluda Medical reported H1 FY26 results with revenue of US$39.4 million, a 17.0% increase.
- Gross margin improved to 49.4%, a 220 basis point increase compared to the prior period.
- Adjusted EBITDA was (US$56.9) million, with cash used in operations at US$60.3 million.
- The company reaffirmed FY26 revenue guidance at US$85 million, indicating 21% growth.
- Saluda's cash balance at the end of December 2025 was US$151.4 million.
- The company's Evoke® System showed positive clinical outcomes, supporting growth strategy.
- Expansion of the US sales force is ahead of schedule, contributing to revenue growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| The a2 Milk Company Limited (A2M) ORDINARY FULLY PAID |
Consumer Staple |
$5,042 |
Becoming a substantial holder
|
26 Feb 2026 9:24AM |
$9.510 |
$6.950 |
fallen by
26.92%
|
|
| Core Lithium Ltd (CXO) ORDINARY FULLY PAID |
Materials |
$777 |
Sale of Spodumene Concentrate Stockpile
|
26 Feb 2026 9:23AM |
$0.245 |
$0.240 |
fallen by
2.04%
|
|
CXO - Price-sensitive ASX Announcement
Full Release
Key Points
- Fixed price agreement with Glencore International AG for sale of ~5,100dmt spodumene concentrate.
- Sale price reflects a Fastmarkets SC6 CIF China equivalent price of US$2,023/dmt.
- Proceeds from sale expected in the June quarter 2026.
- Additional funding to support Finniss Project restart strategy.
- 75,000dmt lithium fines stockpile remains available.
- High quality of Finniss concentrate acknowledged by offtake customers.
- Approved for release by the Board of Core Lithium Ltd.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dicker Data Limited (DDR) ORDINARY FULLY PAID |
Information Technology |
$2,222 |
Annual Report
|
26 Feb 2026 9:23AM |
$10.280 |
$12.250 |
risen by
19.16%
|
|
| Charger Metals NL (CHR) ORDINARY FULLY PAID |
Materials |
$7 |
Further Assays Confirm Very High Grade Xmas Gold Discovery
|
26 Feb 2026 9:23AM |
$0.100 |
$0.081 |
fallen by
19%
|
|
CHR - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade gold confirmed at Xmas Gold Discovery.
- Significant intercepts include 3m at 18.0 g/t Au.
- Project located in Lake Johnston, Yilgarn Province, WA.
- Over 2,000m of trend previously undrilled.
- Current 3,000m RC and diamond drill program underway.
- Assays pending for additional core samples from recent drilling.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$5,189 |
ASX presentation - Half year results 2026
|
26 Feb 2026 9:23AM |
$13.040 |
$10.640 |
fallen by
18.40%
|
|
WOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Worley Limited reported a 5.4% increase in aggregated revenue, reaching $6,312 million for the first half of FY2026 compared to H1 FY2025.
- Energy sector revenue grew by 8.8%, while chemicals decreased by 9.0%, and resources increased by 12.3%.
- Segment EBITA declined by 8.4% to $504 million, with a corresponding decrease in segment margin from 9.2% to 8.0%.
- The company saw strong revenue growth in the Americas, stable performance in EMEA, but a slowdown in APAC due to professional service project completions.
- Normalized operating cash conversion stood at 95.5%, reflecting adjustments made for advance billings.
- The company is targeting over $100 million in annualized savings from FY2027 through cost-out programs.
- Worley maintained a dividend of 25 cents per share, in line with the previous period.
- Significant transformation and restructuring costs were incurred, amounting to $82 million, impacting underlying earnings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EPX Limited (EPX) ORDINARY FULLY PAID |
Information Technology |
$13 |
Half Yearly Report and Accounts
|
26 Feb 2026 9:22AM |
$0.260 |
$0.155 |
fallen by
40.38%
|
|
EPX - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after income tax for the half-year was $2,632,689.
- Total equity increased to $2,414,330.
- Revenue from external sales and recurring contracts totaled $7,863,011.
- Net cash outflow from operating activities was $1,171,654.
- Net cash used in investing activities was $849,534.
- Cash from financing activities was positive due to share issues and borrowings.
- Total assets and liabilities were $13,930,493 and $11,516,163, respectively.
- Expenses included significant employee benefits, legal fees, and finance costs.
- Inventory acquired from Wattwatchers and investments in technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$5,189 |
ASX release - Half year results 2026
|
26 Feb 2026 9:22AM |
$13.040 |
$10.640 |
fallen by
18.40%
|
|
WOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Aggregated revenue for HY26 was $6,312 million, an increase of 5.4% from the previous corresponding period.
- Underlying EBITA remained steady at $377 million, with an EBITA margin of 6.0%.
- Statutory NPATA was $152 million, impacted by transformation and restructuring costs.
- Strong contract wins totaling $9.8 billion, including major projects in the Americas, UK, and Australia.
- Continued efforts in cost management and restructuring are expected to result in $100 million of annualized savings from FY27.
- Worley’s backlog increased to $16.7 billion, showing strong project momentum.
- The Americas contributed significantly to revenue growth, with major projects moving into execution phases.
- Worley focuses on expanding into growth markets beyond energy, chemicals, and resources, including critical infrastructure.
- The company maintains a strong balance sheet with over $2.2 billion in liquidity to manage debt maturities.
- Worley declared an interim dividend of 25 cents per share, payable on 2 April 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Saluda Medical, Inc. (SLD) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$101 |
Half Yearly Report and Accounts
|
26 Feb 2026 9:21AM |
$0.990 |
$0.400 |
fallen by
59.60%
|
|
SLD - Price-sensitive ASX Announcement
Full Release
Key Points
- Saluda Medical, Inc. reported a global revenue increase to US$39.4 million, a 17% rise from the previous period.
- The company has expanded its US sales force, contributing to a 16.7% increase in the number of US implanted patients.
- Saluda Medical completed a common stock financing transaction and an IPO, converting previously issued convertible notes and preferred stock to common stock.
- The company incurred a net loss of US$66.8 million in H1 FY26, an increase from US$53.5 million in the previous corresponding period.
- Adjusted net loss was US$69.4 million due to revenue growth being outpaced by sales and marketing expenses.
- No dividends have been paid or declared, nor does the company recommend dividends.
- Saluda Medical's core product, the Evoke System, is designed for SCS therapy targeting chronic neuropathic pain.
- The financial statements are prepared in accordance with US GAAP and are denominated in US dollars.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Megado Minerals Limited (MEG) ORDINARY FULLY PAID |
Materials |
$14 |
Trading Halt
|
26 Feb 2026 9:21AM |
$0.033 |
$0.019 |
fallen by
42.42%
|
|
MEG - Price-sensitive ASX Announcement
Full Release
Key Points
- Megado Minerals Limited requests a trading halt.
- The halt is pending an announcement related to a proposed acquisition.
- The trading halt ensures management of disclosure obligations.
- Halt to last until March 2, 2026, or an earlier announcement.
- Request made under ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dicker Data Limited (DDR) ORDINARY FULLY PAID |
Information Technology |
$2,222 |
Appendix 4E
|
26 Feb 2026 9:21AM |
$10.280 |
$12.250 |
risen by
19.16%
|
|
DDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory revenue increased by 12.5% to $2,569.1 million.
- Gross sales rose by 15.0% to $3,866.0 million.
- Software and advanced solutions showed strong growth.
- Net profit after tax increased by 8.8% to $85.6 million.
- Total assets as of 31 December 2025 were $1,149.2 million.
- Net debt decreased to $293.0 million.
- Dividends totaled 44.0 cents per share for the year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boss Energy Ltd (BOE) ORDINARY FULLY PAID |
Energy |
$540 |
December 2025 Half-year Financial Report and Appendix 4D
|
26 Feb 2026 9:20AM |
$1.725 |
$1.300 |
fallen by
24.64%
|
|
BOE - Price-sensitive ASX Announcement
Full Release
Key Points
- Boss Energy recorded a net loss after tax of $7.9 million for the period ending December 2025.
- Total revenue increased by 71% to $81.8 million.
- C1 Cash cost reduced to $32/lb (US$21/lb), leading to a new guidance range of $36-$40/lb.
- Production increased to 842k lbs of uranium due to additional wellfields and NIMCIX columns.
- Cash and liquid assets stood at $208.0 million at the end of the period.
- Development focus is on Honeymoon and Alta Mesa Operations.
- Initiated Honeymoon Review, resulting in a material deviation from previous feasibility study assumptions.
- Continued investment in the Honeymoon Uranium Operation and Alta Mesa Operation.
- Corporate restructuring with new appointments including Matthew Dusci as Managing Director and CEO.
- No dividends were paid or recommended.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RAS Technology Holdings Limited (RTH) ORDINARY FULLY PAID |
Industrials |
$28 |
RTH H1 FY26 Results Announcement
|
26 Feb 2026 9:20AM |
$0.750 |
$0.580 |
fallen by
22.67%
|
|
RTH - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased 38% to $13.9 million.
- ARR increased 34% to $24.6 million.
- Successful integration of Hong Kong operations.
- Transformational agreement with LeoVegas.
- Expansion of proprietary full racing solution.
- Positive outlook for H2 FY26 with continued growth expected.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Waterco Limited (WAT) ORDINARY FULLY PAID |
Consumer Discretionary |
$188 |
Update - Notification of buy-back - WAT
|
26 Feb 2026 9:19AM |
$5.080 |
$5.380 |
risen by
5.91%
|
|
| K&S Corporation Limited (KSC) ORDINARY FULLY PAID |
Industrials |
$404 |
Press Release - Interim Dividend Payment Date Correction
|
26 Feb 2026 9:19AM |
$3.360 |
$2.950 |
fallen by
12.20%
|
|
| Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID |
Health Care |
$122 |
Half Yearly Report and Accounts
|
26 Feb 2026 9:19AM |
$0.008 |
$0.560 |
risen by
6,900%
|
|
ATH - Price-sensitive ASX Announcement
Full Release
Key Points
- During the half-year ended 31 December 2025, Alterity Therapeutics advanced its lead asset, ATH434, for treating Multiple System Atrophy (MSA).
- The company reported a net loss of $9,615,849 for the half-year ended 31 December 2025.
- Alterity's regulatory strategy focused on preparations for an End-of-Phase-2 meeting with the FDA for mid-2026.
- ATH434 Phase 2 studies showed clinically meaningful efficacy and safety in treating MSA.
- The company raised approximately A$20 million in September 2025 for ATH434 development activities.
- Alterity engaged in strategic partnerships and external interest for ATH434's commercial potential.
- No dividends were paid or declared during the period ending 31 December 2025.
- The company maintains a going concern basis, with cash and cash equivalents of $49,200,547 as of 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Motorcycle Holdings Limited (MTO) ORDINARY FULLY PAID |
Consumer Discretionary |
$179 |
1H26 Investor Presentation
|
26 Feb 2026 9:19AM |
$2.650 |
$2.420 |
fallen by
8.68%
|
|
Call 1300 880 160
Start a chat
Schedule a call
